Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2017
At a glance
- Drugs PEPIDH1M (Primary)
- Indications Glioma
- Focus Adverse reactions
- 18 Jun 2017 Last checked against ClinicalTrials.gov record.
- 10 Jun 2017 Biomarkers information updated
- 10 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 Jun 2019.